Page 771 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 755

Nonspeci c inhibitors, 537 symptoms, 153 Phlebotomy (see also Venous blood collection)
Normal bone marrow activity, 216 Paroxysmal cold hemoglobinuria, 307 quality

Normal peripheral blood smear, 231, 231 Paroxysmal nocturnal hemoglobinemia testing, assessment, 26
Normochromic anemias, 232 638 patient care partnership, 26
Normochromic erythrocyte, 149 Paroxysmal nocturnal hemoglobinuria (PNH), phlebotomist, 26
Normocytic anemias, 232 131, 294, 638 treatment, 463, 463

Normocytic erythrocyte, 142 clinical signs and symptoms, 307 Photons, 621
Northern blot analysis, 455, 460, 660 epidemiology, 306 Pinocytosis, 60
Nosocomial in ection, 5 etiology, 306 Plasma, 27
Nuclear-cytoplasmic (N:C) ratio, 96 laboratory ndings, 307 Plasma cell disorders, 203–204

Nucleoli, 97 pathophysiology, 306–307 Plasma cell dyscrasias
Nucleosome, 63 reticulocyte count, 308 clinical signs and symptoms, 435, 435
Nucleotide, 653, 655 treatment, 307 emerging therapies, 439, 440b
Nucleus activities Pathogens, 3 epidemiology, 434

apoptosis, 68–70 Pathophysiology etiology, 434–435
meiosis, 70, 70–71 anemia o in ammation (AOI), 265–267 laboratory data, 435–438, 436t–437t, 438, 439
mitosis, 67 aplastic anemia treatment, 438
G0 phase, 68 blood cell destruction, 247 Plasma cell leukemia, 434

interphase, 66–67 bone marrow destruction, 246–247, 247 Plasma cells
M phase, 68 hematopoietic ailure, 246–247 development, 203, 203
Nutritional anemia, 231, 231 immune mediated, 245 kinetics, 201–202
immune system and hematopoietic cells, 246 maturation, 203, 203

O laboratory studies, 246 maturational morphology, 203
Occupational sa ety and health administration hereditary hemochromatosis (HH), 271 nonmalignant disorders, 203–204
(OSHA) iron de ciency anemia (IDA), 262 plasmacytoid lymphocytes, 203
bloodborne pathogens, occupational exposure, 3 Patient care partnership, 26 types, 202

chemical hygiene plan (CHP), 3 PCR (see Polymerase chain reaction) Plasmacytoid lymphocytes, 203
in ectious waste, 11 PCV (see Packed cell volume) Plasminogen, 533
medical waste standards, 11 Pelger-Huët anomaly, 339t, 341, 341 Plasminogen activators, 533
patient’s rights, 5 Pericardial ef usion, 600–601, 601t Plasmodium falciparum, 154–155, 155

personal protective equipment (PPE), 7–8 Pericardial uid Plasmodium malariae, 155, 155
right to know laws, 3 ef usion, 600–601, 601t Plasmodium ovale, 155, 155–156
Oncogenes, 73, 374 laboratory analysis Plasmodium vivax, 154, 154
Oocyst, 152 cell counts, 601 Platelet adhesion, 496, 496–497, 500

Ookinete, 152 cytological examination, 601 Platelet aggregation, 496, 497
Operational iron, 260 gross examination, 601 Platelet count, 692–693
Opsonins, 178 leukocyte dif erential, 601 Platelet disorders vs. blood coagulation disorders,
Opsonization, 178 smears evaluation, 601 522t

Optical detection principle, 619–620 pericardium anatomy, 599–600, 600 Platelet distribution width (PDW), 631
Organs, leukemic in ltration o , 404 Periodic acid-Schif (PAS) in leukocytes, 515, 515 Platelet plug, 490, 497
Orthochromic normoblast (see Metarubricyte) Peripheral blood characteristics, MPNs, 450, 461t Platelets
OSHA (see Occupational sa ety and health Peripheral blood lm evaluation abnormalities, 479–480

administration) complete blood count (CBC) dys unctions types, 516, 516t
Osler-Weber-Rendu syndrome, 505 microscopic examination ow cytometry clinical applications, 635
Osmosis, 59, 60 high power (10×), 219–220 hemostasis unction
Osmotic cytolytic reaction, 294 low power (10×), 219 adhesion, 496, 496–497, 500

Osteoclasts, 169 oil immersion lens (1,000×), 220 aggregation, 497, 497–498, 500
Osteogenesis imper ecta, 507 leukocyte morphology re erence, 221, 222t antiplatelet antibody assays, 500
Oval macrocytes, 146, 147 Peritoneal uid aspirin, 498
Oxidative pathway, 114 ascites, diagnosis o , 599 bleeding time with and without aspirin,

cellular dif erential examination, 598–599 499–500
P ef usion, 596 clopidogrel, 498
Packed cell volume (PCV), 211, 674–675 peritoneum anatomy, 596, 597 clot retraction, 500
Pancytopenia, 88, 244 physical characteristics, 597 dipyridamole, 498

Pappenheimer bodies, 152, 152 total cell count, 597–598, 599t GP IIb/IIIa antagonist, 498–499
Paracentesis, 596 Pernicious anemia, 280, 282–287 overall unctions o , 496
Parameter, 624 Persistent monocyte count, 483 plug consolidation and stabilization, 498,
Paraprotein disorders, 518 Personal protective equipment (PPE) 498b

Parasitic inclusions coats/gowns, 8 prasugrel, 498
babesiosis electronic devices, 8 qualitative assessment o , 218–219, 499, 499b
epidemiology, 156 acial barrier protection, 7–8 semiquantitative assessment, 220–221
etiology, 156 gloves, 7, 8 ticagrelor, 799

laboratory ndings, 156–157 nail care, 8 histograms
signs and symptoms, 156 occlusive bandage, 7–8 Dif Plot normal and abnormal cell popula-
Leishmania sp., 156, 156 shoes, 8 tions, 629, 630
malaria Petechiae, 504–505, 505 electrical impedance, 630, 630

diagnosis, 153 Phagocytosis, 60, 166, 175–176, 176 manual cell counting, 210, 211t
disease cycle, humans, 153, 153 cell movement, 176 qualitative characteristics o (see
disease cycle, mosquito, 152, 153 destruction and debris removal, 179–180 Trombocytopathy)
etiology, 152 digestion, 178–179 Pleural ef usion, 593

molecular testing, 154 engul ment, 178 Pleural uid
morphological eatures, 153t initiation, 176 laboratory analysis
Plasmodium falciparum, 154–155, 155 monocytes, 179 cell count, 594
Plasmodium malariae, 155, 155 phagocytic activity, 179–180 cell dif erential examination, 594–596

Plasmodium ovale, 155, 155–156 Phagosomes, 178–179 cytological examination, 596
Plasmodium vivax, 154, 154 Philadelphia chromosome, 452, 452 physical characteristics, 593, 593t